Anti-Aldob polyclonal antibody (CABT-B388)

Specifications


Host Species
Rabbit
Antibody Isotype
IgG
Species Reactivity
Zebrafish, Human, Mouse, Rat, Bovine
Conjugate
Unconjugated

Applications


Application Notes
IHC-P: 1:100-1:1000
WB: 1:500-1:3000
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.

Target


Alternative Names
fructose-bisphosphate aldolase B; fb25f09; wu:fb25f09; aldob; aldolase b, fructose-bisphosphate

Citations


Have you cited CABT-B388 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling


We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


SHEEP GENE-MAPPING - ASSIGNMENT OF ALDOB, CYP19, WT AND SOX2 BY SOMATIC-CELL HYBRID ANALYSIS

ANIMAL GENETICS

Authors: PAYEN, E; SAIDIMEHTAR, N; PAILHOUX, E; COTINOT, C

Twenty-four hamster-sheep hybrid cell lines representing eleven ovine synteny groups were used to make syntenic assignments for seven loci ALDOB (aldolase B, fructose biphosphate); AMH (anti-Mullerian hormone); CYP19 [cytochrome P-450 aromatase, subfamily XIX (aromatization of androgens)]; WT (Wilms' tumour gene); SOX2 (SRY-related HMG-box gene 2); FSHB (follicle-stimulating hormone, beta polypeptide); and SRY (sex region of Y chromosome). These loci were assigned to synteny groups U11(chr2) (ALDOB); U19 (AMH); U3(chr7) (CYP19); and to chromosomes 15 (WT) and 1 (SOX2). SRY defines the hybrids containing the Y chromosome.

Clinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma

CLINICAL GENITOURINARY CANCER

Authors: Nouhaud, Francois-Xavier; Blanchard, France; Sesboue, Richard; Flaman, Jean-Michel; Sabourin, Jean-Christophe; Pfister, Christian; Di Fiore, Frederic

The present study was performed on frozen tissue samples from 50 patients treated for metastatic clear cell renal cell carcinoma. Using the quantitative multiplex polymerase chain reaction of short fluorescent fragment method, several gene copy number variations present in tumor tissue were found to be associated with worse prognostic factors. Specifically, loss of 9p (CDKN2A), 9q (ALDOB), and 6q (PLG) was associated with poor prognosis factors. In addition, these copy number variations were associated with the prognostic factors. Background: Gene copy number variations (CNVs) have been reported to be frequent in renal cell carcinoma (RCC), with potential prognostic value for some. However, their clinical utility, especially to guide treatment of metastatic disease remains to be established. Our objectives were to assess CNVs on a panel of selected genes and determine their clinical relevance in patients who underwent treatment of metastatic RCC. Patients and Methods: The genetic assessment was performed on frozen tissue samples of clear cell metastatic RCC using quantitative multiplex polymerase chain reaction of short fluorescent fragment method to detect CNVs on a panel of 14 genes of interest. The comparison of the electropherogram obtained from both tumor and normal renal adjacent tissue allowed for CNV identification. The clinical, biologic, and survival characteristics were assessed for their associations with the most frequent CNVs. Results: Fifty patients with clear cell metastatic RCC were included. The CNV rate was 21.4%. The loss of CDKN2A and PLG was associated with a higher tumor stage (P < .05). The loss of PLG and ALDOB was associated with a higher Fuhrman grade (P < .05). The loss of ALDOB was also associated with a worse Heng prognostic score (95% vs. 66%; P = .029) and lower 24-month survival rate (18% vs. 58%; P = .012). The loss of both ALDOB and PLG was frequent (32%) and was associated with a higher tumor stage and grade (P < .05). Conclusion: As expected, we showed that several CNVs were associated with clinical relevance, especially those located on CDKN2A, PLG, and ALDOB, in a homogeneous cohort of patients with clear cell metastatic RCC.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket